Navigation Links
Melatonin may save eyesight in inflammatory disease
Date:11/22/2008

Buenos Aires, Argentina Current research suggests that melatonin therapy may help treat uveitis, a common inflammatory eye disease. The related report by Sande et al., "Therapeutic Effect of Melatonin in Experimental Uveitis," appears in the December issue of The American Journal of Pathology.

People with uveitis develop sudden redness and pain in their eyes, and their vision rapidly deteriorates. Untreated, uveitis can lead to permanent vision loss, accounting for an estimated 10-15% of cases of blindness in the US. Uveitis has a wide variety of causes, including eye injury, cancer, infection, and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. There is currently no optimal treatment for uveitis. Corticoid steroid eye drops are often used; however, long-term corticoid use has many negative side effects, including the possible development of glaucoma.

Researchers lead by Dr. Ruth Rosenstein of The University of Buenos Aires and The National Research Council (CONICET) hypothesized that melatonin, which regulates sleep/wake cycles and reduces jet lag, may be able to prevent the ocular inflammation in uveitis. They found in an experimental model of uveitis that levels of two factors that contribute to inflammation, TNFα and NFκB, were reduced with melatonin treatment. Importantly, melatonin treatment also decreased the appearance of clinical symptoms of uveitis such as inflammation, blood vessel expansion and cataract, and protected the blood-ocular barrier integrity.

Taken together, the data from Sande et al suggest that "melatonin, which lacks adverse collateral effects even at high doses, could be a promising resource in the management of uveitis. Alone or combined with corticosteroid therapy, the anti-inflammatory effects of melatonin may benefit patients with chronic uveitis and decrease the rate and degree of corticosteroid-induced complications." Future studies will aim at understanding the mechanisms governing melatonin protection in the eye.


'/>"/>

Contact: Angela Colmone
acolmone@asip.org
301-634-7953
American Journal of Pathology
Source:Eurekalert

Related biology news :

1. Eat oily fish at least once a week to protect your eyesight in old age
2. Scientists successfully treat new mouse model of inflammatory bowel disease
3. Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment
4. Geisinger study: Inflammatory disease causes blindness
5. Anti-inflammatory drug blocks brain plaques
6. Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
7. New genes found for inflammatory bowel disease in children
8. UC Davis researchers discover new drug target for inflammatory disease
9. Researchers apply systems biology and glycomics to study human inflammatory diseases
10. Antioxidant overload may underlie a heritable human disease
11. Gender, coupled with diabetes, affects vascular disease development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
(Date:11/22/2016)... Nov. 22, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, ... purpose of the trial was to determine the safety, antitumor activity, and recommended ...
(Date:12/7/2016)... , Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dr. Dan Kephart as its chief science ... will assume his responsibilities at Neogen effective Jan. 1. ... director for the agribusiness unit of Thermo Fisher Scientific, ... at Life Technologies. His extensive industry experience also includes ...
Breaking Biology Technology: